Impressions of MARIPOSA Overall Survival and Potential Impact in Current SOC
Panelists discuss how the significant overall survival (OS) benefit demonstrated by the new combination therapy (amivantamab-lazertinib) compared with standard monotherapy makes it a preferred treatment option for most patients despite a slightly increased toxicity and time commitment.
EP: 1.Brief Overview of Current Treatment Landscape for 1L EGFRm NSCLC
EP: 2.Impressions of MARIPOSA Overall Survival and Potential Impact in Current SOC
EP: 3.Evaluating Chemotherapy-Free vs Chemotherapy-Containing Combos in First-Line EGFR-Mutated NSCLC: Pros and Cons
EP: 4.Decision-Making Factors in Choosing Combination Therapies in EGFR-Mutated NSCLC
EP: 5.Insights from MARIPOSA: Impressions of the Intracranial Data
EP: 6.Analysis of MARIPOSA & SKIPPirr Trials: Safety and Quality of Life
EP: 7.Assessing the Adverse Effect Profile of Ami-Laz in Comparison With Other Combination Therapies in EGFRm NSCLC
EP: 8.Looking Ahead and Key Takeaways in EGFRm NSCLC
Video content above is prompted by the following:
MARIPOSA Trial Results for EGFRm NSCLC Treatment
OS Data for Amivantamab-Lazertinib vs Osimertinib
The MARIPOSA trial demonstrates a significant OS benefit for the amivantamab-lazertinib combination compared with osimertinib monotherapy:
- HR of 0.75, indicating a 25% reduction in mortality risk
- Approximately 1 year improvement in median OS
- The OS benefit appears definitive, with final OS data now available
Impact on First-Line Treatment Approach
- Based on the discussion, this combination therapy appears positioned to become a preferred first-line option for EGFR-mutated (EGFRm) non–small cell lung cancer (NSCLC). The panelists strongly suggest that osimertinib monotherapy should now be limited to select cases (older, frail patients).
- Despite requiring more office visits and having somewhat increased toxicity, the survival benefit is considered to outweigh these challenges.
- The panelists anticipate that these data would warrant the highest-level recommendation in treatment guidelines (such as NCCN).
- While acknowledging there is another combination that may read out later in 2025, the available OS data for amivantamab-lazertinib provides good clarity for treatment decisions.
Conclusion
The consensus among the panelists is that OS is the paramount end point for most patients, particularly younger ones, and this combination therapy delivers meaningfully on this metric.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
